This site is intended for healthcare professionals

Predstavenie titulu

Novinky z tohtoročného najvýznamnejšieho stretnutia onkológov 2019

Originálny názov:
Novinky z tohtoročného najvýznamnejšieho stretnutia onkológov

Dátum vydania: 09/2019


Formát: 210×270 mm

Počet strán: 80

Väzba: V1 ?Listy jsou spojeny sponkou ve hřbetu

Jazyk: Slovenčina

Náhľad PDF


Anotácia

Toto číslo slovenskej verzie Event Reportu približuje dianie na každoročnej konferencii Americkej spoločnosti klinickej onkológie, ktorá sa konala 31. mája až 4. júna 2019 v Chicagu. Podrobne sú predstavené témy doplnené abstraktmi, ktoré boli preberané v sekciách: karcinóm prsníka, gynekologické malignity, melanóm, genitourinárne nádory, tumory gastrointestinálneho traktu a karcinóm pľúc.



Obsah

VÝROČNÁ KONFERENCIA ASCO® 2019 Vybrané referáty – karcinóm prsníka
Štefan Korec
 
Adding Ribociclib to First-Line Endocrine Therapy Significantly Improves Survival for Pre-Menopausal Women with Advanced Breast Cancer
 
IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC)
 
Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results
 
Trans-aTTom: Breast Cancer Index for prediction of endocrine benefit and late distant recurrence (DR) in patients with HR+ breast cancer treated in the adjuvant Tamoxifen – To offer more? (aTTom) trial
 
Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study
 
Správa z výročnej konferencie ASCO® 2019 – gynekologické malignity
Branislav Bystrický
 
A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG oncology trial
 
Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage Ib2-IIb cervical cancer, EORTC 55994
 
Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer. A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24
 
ASCO® 2019 – malígny melanóm Opäť krok dopredu
Tomáš Šálek
 
Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma
 
Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO)
 
Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab
 
SPRÁVA Z VÝROČNEJ KONFERENCIE AMERICKEJ ONKOLOGICKEJ SPOLOČNOSTI 2019 Genitourinárne malignity
 
Novel Targeted-Antibody Treatment Produced Responses in Nearly Half of Patients with Advanced Urothelial Cancer
 
Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for metastatic free survival (MFS) after radical prostatectomy (RP): Update at 9 years of the GETUG-AFU 16 phase III
 
EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors
 
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study
 
Najvýznamnejšie klinické správy z konferencie ASCO© 2019 v problematike nádorov gastrointestinálneho traktu
 
Front-Line Pembrolizumab Is Promising Alternative to Chemotherapy for Advanced Gastroesophageal Junction and Gastric Cancers
 
Maintenance Therapy with PARP Inhibitor Olaparib Delays Progression of BRCA-Related Pancreatic Cancer
 
ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC)
 
APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma
 
Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC
 
Karcinóm pľúc na ASCO© 2019
Peter Beržinec
 
Pembrolizumab Increases Historic Survival Rate for Certain People with Advanced Non-Small Cell Lung Cancer
 
Brigatinib in pre-treated patients with ALK-positive advanced NSCLC
 
Preliminary results of single arm phase 2 trial of brigatinib in patients (pts) with progression disease (PD) after next-generation (NG) Anaplastic Lymphoma Kinase (ALK) tyrosine kinase inhibitors (TKIs) in ALK + non-small cell lung cancer (NSCLC)
 
Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3)
 
Adjuvant chemotherapy for pathological stage I non-small cell lung cancer with high-risk factors for recurrence: A multicenter study
 

Tiráž

Vydavateľ: We Make Media Slovakia s.r.o. | IČO: 47 943 661 | Konateľka: MUDr. Ivana Kaderková
Adresa: Bárdošova 2/A, 831 01 Bratislava, Slovenská republika | Tel.: +421 948 422 117
E-mail: info@wemakemedia.sk | www.wemakemedia.sk
Zodpovedná redaktorka: Veronika Lazarová, PhDr. Jana Vytlačilová | Jazyková redaktorka: Mgr. Anetta Letková,
PhDr. Hana Kaiserová | Zlom a grafická úprava: We Make Media Slovakia s.r.o. | ISBN: 978-80-99918-03-2
Vyšlo: september 2019

Akékoľvek kopírovanie a šírenie celého obsahu alebo časti tohto časopisu, či už v tlačenej, alebo elektronickej podobe, je bez výslovného súhlasu vydavateľa prísne zakázané.
Vychádza 1× ročne | 4. ročník | V publikácii boli s povolením Americkej spoločnosti klinickej onkológie použité texty a fotografie zo zdroja:
http://am.asco.org. Texts and photos from the source http://am.asco.org are used with permission of the American Society of Clinical Oncology.
All rights reserved. © 2019 American Society of Clinical Oncology.



Komercia

Partneři projektu